Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

End Of US FDA’s Very Fast Reviews? 2022 Novel Approvals Stayed Close To PDUFA Timeframes

Jan 31 2023

• By Bridget Silverman

• Source: Shutterstock

Related Content

CDER Reviewers Showcase Speed In 2019 With 11 Novel Drugs Approved Within Six Months

Jan 07 2020

US FDA’s Use Of CRLs Hit A High Note In 2022: One-Third Of Novel Agent Decisions Were Not Approvals

Jan 10 2023

FDA’s Novel Approvals Again Led By Oncology And Neurology, But Dermatology Also Shone In 2022

Jan 19 2023

With 37 Novel Approvals in 2022, US FDA CDER’s Five-Year Hot Streak Comes To An End; Gene Therapies Carry CBER To 8 Novel Approvals

Jan 02 2023

Related Companies

Immunocore, Ltd.

Jazz Pharmaceuticals plc

Gilead Sciences, Inc.

Vertex Pharmaceuticals Incorporated

Mallinckrodt plc

Aventis SA

Kyowa Kirin Co., Ltd.

Pfizer Inc.

Alnylam Pharmaceuticals Inc.

Johnson & Johnson

Sanofi

Santen Pharmaceutical Co., Ltd.

Ikaria Holdings, Inc.

Orphan Therapeutics, LLC

Moderna, Inc.

Ferring Pharmaceuticals

Additional Topics

United States Approvals Drug Approval Standards Drug Review Complete Response Letters Regulation Pink Sheet Perspectives US FDA Performance Tracker BioPharmaceutical

More from Pink Sheet Perspectives

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window